Agios Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
AGIO Nasdaq 2836 www.agios.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Agios Pharmaceuticals, Inc.

Exelixis (EXEL) Up 6% Since Last Earnings Report: Can It Continue? - Jun 4th, 2026 9:30 am
How The Tebapivat Setback Is Reframing The Story For Agios Pharmaceuticals (AGIO) - Jun 3rd, 2026 7:12 am
AGIO Secures Global Rights to Late-Stage Rare Blood Disorder Candidate - Jun 2nd, 2026 8:24 am
Agios Pharmaceuticals licenses global rights to Oscotec's SYK inhibitor cevidoplenib - Jun 1st, 2026 10:26 am
AGIO Halts Tebapivat Development in Myelodysplastic Syndromes - Jun 1st, 2026 7:43 am
Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib - Jun 1st, 2026 3:00 am
Why Is Agios Pharmaceuticals (AGIO) Up 8.6% Since Last Earnings Report? - May 29th, 2026 9:30 am
Agios slides after discontinuing development of tebapivat in myelodysplastic syndromes (AGIO) - May 29th, 2026 8:26 am
Exchange-Traded Funds, Equity Futures Rise Pre-Bell Friday Amid US-Iran Deal Hopes - May 29th, 2026 7:16 am
Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes - May 29th, 2026 5:00 am
Allogene CEO to step down; Agios drug fails key test - May 29th, 2026 4:17 am
AGIO's Pyrukynd Gets Approval for Thalassemia in Europe - May 25th, 2026 9:08 am
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia - May 22nd, 2026 8:18 am
Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia - May 22nd, 2026 7:15 am
Agios Pharmaceuticals Touts Strong AQVESME Launch as Sickle Cell Filing Advances - May 19th, 2026 11:03 am
Assessing Agios Pharmaceuticals (AGIO) Valuation After Recent Share Price Volatility - May 15th, 2026 12:13 am
How Agios’ Mitapivat sNDA And New SCD Trial Design At Agios Pharmaceuticals (AGIO) Has Changed Its Investment Story - May 14th, 2026 11:11 pm
Agios sNDA And EHA Plenary Put Mitapivat At Center Of Valuation - May 13th, 2026 1:19 pm
Agios Seeks FDA Nod to Expand Mitapivat Label in Sickle Cell Disease - May 13th, 2026 9:21 am
Sector Update: Healthcare Stocks Gain in Afternoon Trading - May 12th, 2026 11:54 am